Literature DB >> 352612

Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue--a new approach to birth control?

S J Nillius, C Bergquist, L Wide.   

Abstract

A stimulatory luteinizing hormone-releasing hormone (LRH) analogue D-Ser(TBU)6-EA10-LRH was administered subcutaneously once daily in a dose of 5 microgram to four regularly menstruating women. Treatment was instituted within the first three days of the menstrual bleeding and continued for 22--30 days. Ovulation was inhibited in all the women during the treatment cycle. The treatment resulted in disturbances in the pituitary gonadotropin secretion which presumably led to disordered follicular menuration and anovulation. The maximum follicle-stimulating hormone (FSH) and luteinizing hormone (LH) responses to the LRH analogue were obtained during the first few days of treatment. The gonadotropin responses then rapidly decreased during the prolonged treatment. This change in the pituitary responsiveness probably prevented the release of a normal preovulatory LH surge. After the treatment, all the women resumed normal ovulatory menstrual cycles. The results suggest that it might be possible to use stimulatory LRH analogues for birth control.

Entities:  

Keywords:  Biology; Clinical Research; Contraception; Contraception Research; Contraceptive Mode Of Action; Endocrine System; Estradiol--analysis; Estrogens; Family Planning; Female Contraception; Follicle Stimulating Hormone--analysis; Gonadotropins; Gonadotropins, Pituitary; Hormones; Human Volunteers; Injectables; Luteinizing Hormone--analysis; Menstrual Cycle; Ovulation Suppression; Physiology; Pituitary Hormone Releasing Hormones--therapeutic use; Progestational Hormones; Progesterone--analysis; Research Methodology

Mesh:

Substances:

Year:  1978        PMID: 352612

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  9 in total

Review 1.  Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile.

Authors:  R N Brogden; M M Buckley; A Ward
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

2.  Influence of experimental rhinitis on the gonadotropin response to intranasal administration of buserelin.

Authors:  C Larsen; M Niebuhr Jørgensen; B Tommerup; N Mygind; E E Dagrosa; H G Grigoleit; V Malerczyk
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 3.  Controlled-release delivery systems for hormones. A review of their properties and current therapeutic use.

Authors:  L R Beck; V Z Pope
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

Review 4.  Breast cancer prevention through modulation of endogenous hormones.

Authors:  D V Spicer; M C Pike
Journal:  Breast Cancer Res Treat       Date:  1993-11       Impact factor: 4.872

5.  Similar luteinizing hormone-releasing hormone binding sites in rat anterior pituitary and ovary.

Authors:  J J Reeves; C Séguin; F A Lefebvre; P A Kelly; F Labrie
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

Review 6.  GnRH agonists and antagonists. Current clinical status.

Authors:  M Filicori; C Flamigni
Journal:  Drugs       Date:  1988-01       Impact factor: 9.546

7.  The treatment of postmenopausal women with advanced breast cancer with buserelin.

Authors:  J H Waxman; S J Harland; R C Coombes; P F Wrigley; J S Malpas; T Powles; T A Lister
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

8.  Effect of chronic treatment with [D-Ala6, des-Gly-NH210]LHRH ethylamide on ovarian histology in the rat.

Authors:  C Séguin; G Pelletier; F Labrie
Journal:  Cell Tissue Res       Date:  1982       Impact factor: 5.249

Review 9.  Chemotherapy and the adult gonad: a review.

Authors:  J Waxman
Journal:  J R Soc Med       Date:  1983-02       Impact factor: 18.000

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.